article Open AccessTop 1% cited

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema

Ophthalmology · 2014 · Vol. 121(10) · pp. 1904–1914

David S. Boyer✉(Retina Vitreous Associates Medical Group)Young Hee Yoon(University of Ulsan)Rubens Belfort(Universidade Federal de São Paulo)Francesco Bandello(Vita-Salute San Raffaele University)Raj K. Maturi(Midwest Eye Institute)Albert J. Augustin(Städtisches Klinikum Karlsruhe)Xiaoyan Li(Allergan (United States))Harry Cui(Allergan (United States))Yehia Hashad(Allergan (United States))Scott M. Whitcup(Allergan (United States))

View via DOI Publisher page

Abstract

The DEX implant 0.7 mg and 0.35 mg met the primary efficacy endpoint for improvement in BCVA. The safety profile was acceptable and consistent with previous reports.

Retinal Diseases and Treatments Retinal Imaging and Analysis Glaucoma and retinal disordersMedicineImplantDexamethasoneClinical endpointRandomized controlled trialVisual acuityIntraocular pressureAdverse effectOphthalmologyMacular edema

MeSH terms

AdultAgedAged, 80 and overAnti-Inflammatory AgentsDexamethasoneDiabetic RetinopathyDrug ImplantsFemaleHumansMacular EdemaMaleMiddle AgedVisual AcuityArea Under CurveIntravitreal Injections